Key result
Pharmacomechanical thrombolysis is the most promising percutaneous method for treating acute deep vein thrombosis, though randomized trials are needed to confirm long-term benefits and indications.
Why the study?
What are the roles and limitations of percutaneous options for the treatment of acute deep vein thrombosis?
What are the roles and limitations of percutaneous options for the treatment of acute deep vein thrombosis?
Pharmacomechanical thrombolysis is currently the most promising percutaneous method for treating acute DVT, requiring highly individualized patient selection.
Requires cautious individualized use in acute DVT; leaves open long-term benefits and indications pending RCTs.
Anticoagulant therapy is associated with poor late limb outcomes in many patients with deep vein thrombosis (DVT). Because systemic thrombolysis and surgical thrombectomy have inherent limitations, image-guided percutaneous thrombus removal is currently favored. Pharmacologic thrombolysis is effective in removing thrombus, but long-term benefit has not been conclusively demonstrated and major bleeding rates appear to be higher than those observed with anticoagulation alone. Percutaneous mechanical thrombectomy is limited as a stand-alone DVT treatment method by inability to clear large thrombosed veins completely and by pulmonary embolism. Pharmacomechanical thrombolysis represents the most promising currently available method to treat DVT. Randomized trials with long-term follow-up are needed to determine the appropriate indications for these procedures. In the meantime, a highly individualized approach to selection of patients is recommended, taking into account the chronicity and anatomic extent of DVT, the presence of circulatory compromise, the patient's bleeding risk profile, life expectancy, and anticipated activity level.
No takes yet. Share an insight, caveat, or question.
Vedantham et al. (2005) conducted a review in Deep vein thrombosis (DVT). Pharmacomechanical thrombolysis vs. Anticoagulation alone was evaluated. Pharmacomechanical thrombolysis is the most promising percutaneous method for treating acute deep vein thrombosis, though randomized trials are needed to confirm long-term benefits and indications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: